Biostability

Biostability designates the resistance of biological pharmaceutical products to degradation, loss of structure, or reduction in biological activity during storage, handling, and administration, encompassing physical stability including aggregation and particle formation, chemical stability addressing degradation reactions, and functional stability maintaining potency and biological activity.

The biopharmaceutical industry evaluates biostability extensively throughout development as biologics are inherently more susceptible to degradation than small molecules due to their complex structures and sensitivity to environmental conditions. Stability-indicating analytical methods detect changes in relevant quality attributes over time under defined storage conditions. Forced degradation studies identify degradation pathways informing formulation and packaging strategies. Accelerated stability studies at elevated temperatures provide early prediction of long-term stability. Real-time stability data from ICH-specified conditions support shelf life assignment. In-use stability studies evaluate stability after reconstitution, dilution, or during infusion. As biologic products become more structurally complex and global distribution requires extended shelf lives, biostability assessment and improvement through formulation innovation continue ensuring reliable therapeutic performance.